Zdrowie i gospodarka · 26/08/2021
FDA Releases Draft Guidance for Alternative Dosing Regimens of PD-1/PD-L1 Blocking Antibodies for Cancer Treatment
The FDA is releasing a draft guidance that provides recommendations for alternative dosing regimens of PD-1/PD-L1 blocking antibodies for cancer treatment, based on accumulated scientific and regulatory experience with these drugs.
Source: Federal Register — Food and Drug AdministrationOpen original release →